Otonomy to Host Investor and Analyst Day on October 7, 2016
29 sept. 2016 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, Sept. 29, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Otonomy Announces OTIPRIO® Data Presentation and Symposium at American Academy of Otolaryngology - Head and Neck Surgery Foundation Annual Meeting
13 sept. 2016 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, Sept. 13, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
Otonomy Initiates Patient Enrollment in Single Phase 3 Clinical Trial of OTIPRIO™ in Patients with Acute Otitis Externa
09 juin 2016 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, June 09, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Otonomy Announces Assignment of C Code and Pass-Through Payment Status for OTIPRIO™
20 mai 2016 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, May 20, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Otonomy Announces OTIPRIO™ Data Presentation and Symposium at Combined Otolaryngology Spring Meetings
16 mai 2016 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, May 16, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
Otonomy Announces Phase 3 Clinical Trial Plan for OTIPRIO™ in Otitis Externa Patients Based on Successful End-of-Phase 2 Review by FDA
18 avr. 2016 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, April 18, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
Otonomy Added to NASDAQ Biotechnology Index
15 déc. 2015 07h00 HE
|
Otonomy, Inc.
SAN DIEGO, Dec. 15, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Otonomy Announces FDA Approval of OTIPRIO(TM) for the Treatment of Pediatric Patients Undergoing Tympanostomy Tube Placement Surgery
11 déc. 2015 07h30 HE
|
Otonomy, Inc.
U.S. Commercial Launch Expected in the First Quarter of 2016
Webcast and Conference Call at 8:30 a.m. EST Today
SAN DIEGO, Dec. 11, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a...
Otonomy Initiates Open-Label Clinical Trial for OTIPRIO(TM) in Pediatric Patients With History of Otitis Media Requiring Tympanostomy Tubes
03 nov. 2015 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, Nov. 3, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
U.S Bacterial Conjunctivitis Drugs Market Will Reach US& 439.8 Million in 2024 by Persistence Market Research
13 juil. 2015 03h53 HE
|
Persistence Market Research
New York, July 13, 2015 (GLOBE NEWSWIRE) -- According to a new market report published by Persistence Market Research "The U.S Market Study on Bacterial Conjunctivitis Drugs: fluoroquinolones to be...